Opendata, web and dolomites

NEXTER SIGNED

Next generation eco-friendly, microbiome preserving and reduced resistance therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEXTER project word cloud

Explore the words cloud of the NEXTER project. It provides you a very rough idea of what is the project "NEXTER" about.

dozes    microbiome    motifs    decrease    emergence    selective    medicine    pathogenic    prevent    bacterial    beneficial    antibiotics    aureus    stop    perfecting    ribosomal    additional    contaminate    drugs    designed    capacity    pharma    resistance    cells    antibiotic    lower    powerful    causing    protecting    human    unpredictable    attempt    enterococcus    moieties    company    hence    chemical    structural    designing    least    drug    delivered    poc    shown    partnership    biosynthesis    pseudomonas    commercialize    outcome    contamination    desperately    innovative    companies    discovered    alongside    amr    attaching    antimicrobial    rapid    escape    strategic    ribosome    plan    protein    strengthen    primary    pharmaceuticals    ip    health    revolutionary    selectivity    degradable    species    negligible    harm    spread    clinically    technological    modern    compounds    strategy    distinction    synthetic    pathogen    environmental    pathogens    resistant    efforts    environment    inhibit    global    mechanisms    network    strains    bacteria    preserve    commercialization   

Project "NEXTER" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

 Project objective

The rapid emergence and spread of Multi-drug Antimicrobial Resistance (AMR), alongside the negligible efforts of the major pharmaceuticals companies in the development of new antibiotics, result in a major global concern of modern medicine. Moreover, the currently clinically used antibiotics contaminate the environment and may harm the human microbiome, causing unpredictable health concerns. We discovered that by targeting species-specific ribosome unique structural motifs, identified by us, using our designed degradable novel synthetic lead compounds, it is possible to inhibit protein biosynthesis in bacteria. Our approach should enable distinction between pathogenic and non-pathogenic bacteria and between bacterial and human ribosome. This drug selectivity should decrease resistance, preserve the beneficial microbiome and allow usage of lower antibiotics dozes. Furthermore, the designed degradable lead compounds should prevent additional environmental contamination. Hence, our approach allows designing innovative powerful selective antibiotics that escape the existing resistance mechanisms. Several of the primary designed compounds shown to stop the growth of the multi-resistant S. aureus human pathogen were delivered into the bacterial cells by attaching specific chemical moieties to them. In this PoC we plan to design similar compounds for other human pathogens, such as Enterococcus and Pseudomonas species, where revolutionary effective antibiotic drugs against their resistant strains is desperately needed. In addition to the technological PoC in this project, we will attempt pre-commercialization studies aiming at perfecting the commercialization strategy, protecting the IP and strengthen the network for best possible commercialization outcome. The general objective is to establish at least one strategic partnership with a pharma company which has the capacity to further test, develop and commercialize antibiotics that exploit ribosomal novel unique targets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEXTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEXTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

RESOURCE Q (2019)

Efficient Conversion of Quantum Information Resources

Read More  

SoftHandler (2019)

Commercial feasibility of an integrated soft robotic system for industrial handling

Read More  

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More